The aim of our study was to elucidate whether circulating growth factors—GDF-15, Ang-2, VEGF-A, FGF-2, and FGF-21—could be proposed as clinically relevant biomarkers to improve risk stratification in AS patients. This evidence concerns the gene VEGFA and aortic valve stenosis.